Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Open-label Non-inferiority Phase 3 Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm)

NCT03669783 is registered in ClinicalTrials.gov with Assistance Publique Hopitaux De Marseille as lead sponsor.

NCT NCT03669783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03669783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Open-label Non-inferiority Phase 3 Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm)
Lead sponsor
Assistance Publique Hopitaux De Marseille
Phase
Phase 3
Overall status
Recruiting
Start date
February 3, 2023
Completion date
October 3, 2033
Enrollment
110 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

childhood renal tumor